Artivion (NYSE:AORT) Trading Up 8.2% – Here’s Why

Artivion, Inc. (NYSE:AORT)’s share price rose 8.2% during mid-day trading on Tuesday . The company traded as high as $28.56 and last traded at $28.4550. 380,290 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 589,164 shares. The stock had previously closed at $26.31.

Analysts Set New Price Targets

AORT has been the subject of a number of recent research reports. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research report on Monday, June 1st. Needham & Company LLC restated a “buy” rating and set a $44.00 target price on shares of Artivion in a report on Monday, July 20th. Weiss Ratings downgraded shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday. Finally, Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.67.

Artivion Price Performance

The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -405.33 and a beta of 1.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a 50-day simple moving average of $23.95 and a two-hundred day simple moving average of $30.71.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The company had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, equities research analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.

Insider Transactions at Artivion

In related news, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares in the company, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. The trade was a 42.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AORT. BlackRock Inc. bought a new stake in Artivion in the 2nd quarter valued at $149,965,000. Vanguard Group Inc. boosted its position in Artivion by 4.7% during the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the period. Morgan Stanley boosted its position in Artivion by 0.8% during the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after purchasing an additional 18,248 shares during the period. State Street Corp increased its holdings in shares of Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after purchasing an additional 44,641 shares during the last quarter. Finally, Fred Alger Management LLC increased its holdings in shares of Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock valued at $62,603,000 after purchasing an additional 55,322 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.